Can cannabis compounds boost opioid addiction treatment?
NCT ID NCT07148206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two FDA-approved cannabinoids—dronabinol (synthetic THC) and epidiolex (CBD)—to standard buprenorphine treatment can help people with opioid use disorder stay in treatment and reduce opioid use. The trial will enroll 40 adults who recently started buprenorphine and still have withdrawal symptoms or use other opioids. Participants will take the cannabinoids or placebos for 12 weeks, and researchers will track how many stay in treatment and test positive for buprenorphine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dronabinol (synthetic THC) and Epidiolex (CBD)
What this could lead to
If it works, this could offer a new way to help people early in opioid addiction treatment stay on track and avoid relapse.
What could go wrong
This is a small pilot study with only 40 people, so results may not apply widely. Adding cannabinoids could cause side effects or interact with buprenorphine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Health System (Montefiore) Buprenorphine Treatment Network
The Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••